Tirzepatide and Nateglinide: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Nateglinide
Tirzepatide
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased risk of hypoglycemia
Interaction Deep Dive
Concomitant use of tirzepatide with an insulin secretagogue (e.g., sulfonylurea) or with insulin may increase the risk of hypoglycemia. Consider lowering the dose of the insulin secretagogue or insulin to reduce hypoglycemia risk12. In patients with diabetes mellitus, monitor blood glucose prior to starting tirzepatide and during tirzepatide treatment 2.
Why it happens (mechanism)
Additive hypoglycemic effects
Literature reports
1 report — tap to read
a) In a trial of patients with type 2 diabetes mellitus, patients taking tirzepatide in combination with an insulin secretagogue (e.g., sulfonylurea) had an increased risk of hypoglycemia (10.3%) compared to tirzepatide-treated patients not taking a sulfonylurea (2.1%). There is also an increased risk of hypoglycemia in patients treated with tirzepatide in combination with insulin 2.
Common questions
Can I take Tirzepatide and Nateglinide together?
Increased risk of hypoglycemia Always confirm with your pharmacist or prescriber before making any change.
How serious is the Tirzepatide and Nateglinide interaction?
It is rated moderate. Can be significant — usually manageable with monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Tirzepatide or Nateglinide need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
References (2)
- Product Information: MOUNJARO(TM) subcutaneous injection, tirzepatide subcutaneous injection. Lilly USA LLC (per FDA), Indianapolis, IN, 2022. DailyMed
- Product Information: ZEPBOUND(TM) subcutaneous injection, tirzepatide subcutaneous injection. Eli Lilly and Company (per FDA), Indianapolis, IN, 2023. DailyMed
Keep reading about Nateglinide
Keep reading about Tirzepatide
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist